Cancer Diagnostics – News and Features

A new study on human tissue and plasma shows the blood test may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.

Measuring ctDNA could offer a new approach to identifying non-small cell lung cancer patients in greater need of additional treatments during immunotherapy.

The midbody remnant – a signaling organelle that forms during mitosis – has been shown to be packed with genetic material that can play a role in cancer development.

Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.

Measuring circulating tumor DNA may lead to alternative treatment options and better outcomes for patients with advanced BRAF-negative melanoma, report investigates in The Journal of Molecular Diagnostics.

A new study could help doctors decide the best treatment strategy for patients with lung cancer that has spread beyond the original tumor but has not spread all over the body.

Lynch syndrome is an inherited genetic condition that significantly increases the risk of multiple cancers. Researchers have discovered new genetic markers to identify Lynch syndrome-associated colorectal cancer with high accuracy.

Researchers have shown for the first time that breast milk from breast cancer patients contains tumor DNA, known as circulating tumor DNA (ctDNA). This can be detected through liquid biopsy in breast milk.

Using a standardized assessment, researchers in the UK compared the performance of a commercially available AI algorithm with human readers of screening mammograms.

A new liquid biopsy platform has been developed that uses RNA "dark matter" to diagnose cancer types including pancreatic, lung and esophageal, in the early stages.